Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
The latest update is out from Chimeric Therapeutics Ltd. ( (AU:CHM) ).
Chimeric Therapeutics Limited has announced the issuance of 5,435,254 unquoted securities, set to expire on March 31, 2026, with an exercise price of $0.004. This issuance is part of previously announced transactions and is not intended to be quoted on the ASX, potentially impacting the company’s financial structure and stakeholder interests.
More about Chimeric Therapeutics Ltd.
Chimeric Therapeutics Limited operates in the biotechnology industry, focusing on developing innovative therapies. The company is primarily engaged in the research and development of cell therapies for cancer treatment, aiming to provide advanced solutions in the field of oncology.
Technical Sentiment Signal: Sell
Current Market Cap: A$9.75M
For detailed information about CHM stock, go to TipRanks’ Stock Analysis page.